Drugs that covalently modify DNA are components of most chemotherapy regimens, often serving as first‐line treatments. Classically, the reactivity and selectivity of DNA alkylating agents has been determined in vitro… Click to show full abstract
Drugs that covalently modify DNA are components of most chemotherapy regimens, often serving as first‐line treatments. Classically, the reactivity and selectivity of DNA alkylating agents has been determined in vitro with short oligonucleotides. A statistically sound analysis of sequence preferences of alkylating agents is untenable with serial analysis methods because of the combinatorial explosion of sequence possibilities. Next‐generation sequencing (NGS) is ideally suited for the broad characterization of sequence or structure selectivities because it analyzes many sequences at once. Herein, NGS is used to report on the chemoselectivity of alkylating agents on RNA and this technology is applied to the previously uncharacterized alkylating agent trimethylsilyl diazomethane.
               
Click one of the above tabs to view related content.